KROS
Keros Therapeutics, Inc. NASDAQ Listed Apr 8, 2020$11.60
After hrs
$12.07
+0.00%
Mkt Cap $431.8M
52w Low $10.41
9.8% of range
52w High $22.55
50d MA $11.76
200d MA $15.53
P/E (TTM)
4.9x
EV/EBITDA
6.8x
P/B
1.4x
Debt/Equity
0.1x
ROE
28.7%
P/FCF
7.2x
RSI (14)
—
ATR (14)
—
Beta
0.99
50d MA
$11.76
200d MA
$15.53
Avg Volume
412.3K
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
99 Hayden Avenue · Lexington, MA 02421 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | AMC | -0.49 | -0.86 | -75.5% | 13.77 | -5.7% | -15.0% | -17.9% | -17.6% | -15.9% | -18.2% | — |
| Nov 5, 2025 | AMC | -1.11 | -0.18 | +83.8% | 15.65 | +3.1% | +3.3% | +3.5% | +8.9% | +8.0% | +11.6% | — |
| Aug 6, 2025 | AMC | -1.14 | -0.76 | +33.3% | 14.41 | -2.9% | -7.3% | -4.7% | -7.4% | -4.9% | -3.1% | — |
| May 6, 2025 | AMC | -0.01 | 3.62 | +9999.0% | 13.76 | +3.9% | -0.4% | +1.9% | -0.8% | -0.1% | -2.1% | — |
| Feb 26, 2025 | AMC | -1.36 | -1.14 | +16.2% | 10.94 | +0.4% | +0.6% | +1.3% | +1.5% | +5.9% | +6.7% | — |
| Nov 6, 2024 | AMC | -1.26 | -1.41 | -11.9% | 66.45 | -0.2% | +1.1% | +2.2% | +2.6% | -2.4% | -5.1% | — |
| Aug 7, 2024 | AMC | -1.23 | -1.25 | -1.6% | 45.40 | -1.3% | -2.2% | -0.0% | -1.2% | -1.7% | -4.5% | — |
| May 8, 2024 | AMC | -1.31 | -1.21 | +7.6% | 58.24 | +2.5% | -1.1% | -6.8% | -7.3% | -9.3% | -6.6% | — |
| Feb 28, 2024 | AMC | -1.38 | -1.34 | +2.9% | 68.07 | +5.8% | -0.8% | +1.1% | +1.4% | -1.8% | -3.1% | — |
| Nov 6, 2023 | AMC | -1.34 | -1.33 | +0.7% | 31.69 | -0.3% | +0.5% | -2.1% | -7.0% | -6.7% | -5.4% | — |
| Aug 7, 2023 | AMC | -1.34 | -1.27 | +5.2% | 40.42 | -1.0% | -8.7% | -10.0% | -9.3% | -11.4% | -12.5% | — |
| May 4, 2023 | AMC | -1.13 | -1.26 | -11.5% | 45.52 | +0.0% | -3.1% | -5.3% | -2.8% | -1.1% | -1.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $13.77 | $12.98 | -5.7% | -15.0% | -17.9% | -17.6% | -15.9% | -18.2% |
| Nov 28 | BofA Securities | Maintains | Neutral → Neutral | — | $17.50 | $17.71 | +1.2% | -0.1% | -1.8% | -3.8% | +3.4% | +15.8% |
| Nov 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.90 | $16.90 | +0.0% | +3.4% | +2.4% | +2.1% | +2.8% | +3.8% |
| Nov 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $17.04 | $17.11 | +0.4% | -0.8% | +2.5% | +1.5% | +1.3% | +1.9% |
| Nov 6 | Wedbush | Maintains | Neutral → Neutral | — | $15.65 | $16.13 | +3.1% | +3.3% | +3.5% | +8.9% | +8.0% | +11.6% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.36 | $13.32 | -0.3% | +2.8% | -0.1% | +2.6% | +4.5% | +7.9% |
| Jun 10 | BofA Securities | Downgrade | Buy → Neutral | — | $14.09 | $13.78 | -2.2% | -2.4% | -2.1% | -3.2% | -3.8% | -3.1% |
| May 30 | Wedbush | Maintains | Neutral → Neutral | — | $14.02 | $14.01 | -0.1% | +0.9% | +4.6% | +6.6% | +5.7% | +7.8% |
| May 12 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $13.65 | $13.78 | +1.0% | +0.7% | -1.3% | -0.4% | +2.8% | +3.1% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.71 | $13.74 | +0.2% | +2.3% | -0.4% | +0.2% | -1.8% | -0.9% |
| Apr 9 | Truist | Maintains | Buy → Buy | — | $9.76 | $9.54 | -2.3% | +5.8% | +25.4% | +24.8% | +30.5% | +34.1% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.19 | $10.10 | -0.9% | -6.3% | -1.5% | +0.9% | -2.1% | -2.1% |
| Apr 1 | Wedbush | Maintains | Neutral → Neutral | — | $10.19 | $10.10 | -0.9% | -6.3% | -1.5% | +0.9% | -2.1% | -2.1% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.94 | $10.98 | +0.4% | +0.6% | +1.3% | +1.5% | +5.9% | +6.7% |
| Feb 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $10.94 | $10.98 | +0.4% | +0.6% | +1.3% | +1.5% | +5.9% | +6.7% |
| Jan 21 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $10.86 | $11.46 | +5.5% | +5.1% | +4.9% | +10.7% | +9.0% | +5.4% |
| Jan 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.52 | $11.00 | +4.6% | +3.2% | +8.5% | +8.3% | +14.3% | +12.5% |
| Jan 17 | Wedbush | Downgrade | Outperform → Neutral | — | $10.52 | $11.00 | +4.6% | +3.2% | +8.5% | +8.3% | +14.3% | +12.5% |
| Jan 17 | Guggenheim | Maintains | Neutral → Neutral | — | $10.52 | $11.00 | +4.6% | +3.2% | +8.5% | +8.3% | +14.3% | +12.5% |
| Jan 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $10.42 | $10.61 | +1.8% | +1.0% | +4.2% | +9.5% | +9.3% | +15.4% |
| Jan 16 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $10.42 | $10.61 | +1.8% | +1.0% | +4.2% | +9.5% | +9.3% | +15.4% |
| Dec 23 | Truist | Maintains | Buy → Buy | — | $17.03 | $16.98 | -0.3% | +0.5% | -1.9% | -1.3% | -3.6% | -8.2% |
| Dec 16 | Guggenheim | Downgrade | Buy → Neutral | — | $18.83 | $18.25 | -3.1% | +3.1% | -4.4% | -9.0% | -10.1% | -9.6% |
| Dec 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $18.83 | $18.25 | -3.1% | +3.1% | -4.4% | -9.0% | -10.1% | -9.6% |
| Dec 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $18.43 | $18.76 | +1.8% | +2.2% | +5.4% | -2.3% | -7.1% | -8.2% |
| Dec 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.43 | $18.76 | +1.8% | +2.2% | +5.4% | -2.3% | -7.1% | -8.2% |
| Dec 13 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $18.43 | $18.76 | +1.8% | +2.2% | +5.4% | -2.3% | -7.1% | -8.2% |
| Dec 12 | BTIG | Downgrade | Buy → Neutral | — | $68.65 | $18.70 | -72.8% | -73.2% | -72.6% | -71.7% | -73.8% | -75.0% |
| Dec 12 | TD Cowen | Downgrade | Buy → Hold | — | $68.65 | $18.70 | -72.8% | -73.2% | -72.6% | -71.7% | -73.8% | -75.0% |
| Dec 12 | William Blair | Downgrade | Outperform → Market Perform | — | $68.65 | $18.70 | -72.8% | -73.2% | -72.6% | -71.7% | -73.8% | -75.0% |
| Dec 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $66.31 | $67.76 | +2.2% | +3.5% | -72.2% | -71.6% | -70.7% | -72.9% |
| Dec 5 | Guggenheim | Maintains | Buy → Buy | — | $67.79 | $67.79 | +0.0% | -4.7% | +3.3% | -1.0% | -2.2% | +1.3% |
| Dec 4 | Guggenheim | Maintains | Buy → Buy | — | $62.28 | $63.82 | +2.5% | +8.8% | +3.7% | +12.4% | +7.8% | +6.5% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $66.45 | $66.30 | -0.2% | +1.1% | +2.2% | +2.6% | -2.4% | -5.1% |
| Sep 12 | BofA Securities | Maintains | Buy → Buy | — | $54.75 | $54.50 | -0.5% | +3.0% | +4.1% | +1.6% | +0.5% | +1.8% |
| Jun 18 | Truist | Maintains | Buy → Buy | — | $44.58 | $43.57 | -2.3% | +0.2% | +1.9% | +4.2% | +4.3% | +2.4% |
| Jun 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $44.58 | $43.57 | -2.3% | +0.2% | +1.9% | +4.2% | +4.3% | +2.4% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $58.24 | $59.70 | +2.5% | -1.1% | -6.8% | -7.3% | -9.3% | -6.6% |
| Mar 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $66.11 | $59.20 | -10.5% | -2.2% | +0.1% | +1.2% | -3.2% | -3.2% |
| Mar 13 | Truist | Maintains | Buy → Buy | — | $67.55 | $67.68 | +0.2% | +0.2% | -4.0% | -0.3% | -5.5% | -5.0% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.50 | $67.73 | +0.3% | +2.0% | +2.2% | -1.0% | -2.3% | +3.3% |
| Nov 13 | Wedbush | Maintains | Outperform → Outperform | — | $29.57 | $29.44 | -0.4% | +1.4% | +7.2% | +7.7% | +6.5% | +2.4% |
| Aug 31 | Wedbush | Maintains | Outperform → Outperform | — | $35.58 | $35.50 | -0.2% | -1.3% | +1.9% | -0.4% | +0.7% | +0.5% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.90 | $36.91 | +0.0% | -1.5% | -0.7% | -2.9% | -4.2% | -5.8% |
| Aug 8 | Wedbush | Maintains | Outperform → Outperform | — | $40.42 | $40.01 | -1.0% | -8.7% | -10.0% | -9.3% | -11.4% | -12.5% |
| Jun 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.96 | $47.60 | -2.8% | -10.4% | -16.3% | -18.4% | -21.2% | -20.7% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $44.12 | $43.83 | -0.7% | -2.3% | +0.3% | +2.0% | +1.6% | +1.9% |
| May 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $45.52 | $45.54 | +0.0% | -3.1% | -5.3% | -2.8% | -1.1% | -1.5% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $59.32 | $58.63 | -1.2% | -12.0% | -13.9% | -9.4% | -18.5% | -25.4% |
| Feb 14 | Cowen & Co. | Maintains | Outperform → Outperform | — | $53.02 | $53.52 | +0.9% | +7.1% | +7.0% | +2.6% | +3.7% | +1.1% |
No insider trades available.
8-K · 8.01
!! High
Keros Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Keros Therapeutics announced a collaboration with Massachusetts General Brigham's Healey ALS Center, potentially expanding clinical development pathways for its pipeline candidates in amyotrophic lateral sclerosis treatment.
Mar 9
8-K
Keros Therapeutics, Inc. -- 8-K Filing
Keros Therapeutics reported Q4 2025 financial results and business highlights as a clinical-stage biopharmaceutical company developing novel therapeutics for various disorders.
Mar 4
8-K · 7.01
! Medium
Keros Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Keros Therapeutics disclosed a presentation via 8-K filing, providing investors access to updated company information through its website and attached exhibit materials.
Mar 4
8-K · 5.02
!!! Very High
Keros Therapeutics, Inc. -- 8-K 5.02: Executive Change
Keros Therapeutics appoints Charles Newton as a Class III director, strengthening its board composition and governance structure.
Feb 26
8-K · 7.01
! Medium
Keros Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Keros Therapeutics will present at two major healthcare investor conferences in March 2026, providing opportunities for investors to hear directly from management about company developments.
Feb 18
Data updated apr 25, 2026 6:02pm
· Source: massive.com